Evidence for the existence of an organ specific, androgen-independent pathway of progression in patients with metastatic prostate cancer

Jer‐Tsong Hsieh(The University of Texas Southwestern Medical Center), Christopher J. Logothetis(The University of Texas MD Anderson Cancer Center), Laury Finn(The University of Texas MD Anderson Cancer Center), Wei Song(Qingdao University), Hsi-Chin Wu, Yan Wang(The University of Texas MD Anderson Cancer Center), Wěi Li(Shougang (China))
Urologic Oncology Seminars and Original Investigations
March 1, 1995
10.1016/1078-1439(95)00023-b
Cited by 1

Related Papers

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
HIF-1α pathway: role, regulation and intervention for cancer therapy
|Acta Pharmaceutica Sinica B|2015|1.9k
The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients
|Science Translational Medicine|2016|416
Tumor suppressive role of an androgen-regulated epithelial cell adhesion molecule (C-CAM) in prostate carcinoma cell revealed by sense and antisense approaches.
|PubMed|1995|174
Multiple Reaction Monitoring of mTRAQ-Labeled Peptides Enables Absolute Quantification of Endogenous Levels of a Potential Cancer Marker in Cancerous and Normal Endometrial Tissues
|Journal of Proteome Research|2008|172